• Bulletin of the Korean Chemical Society
• /
• 제32권1호
• /
• pp.183-185
• /
• 2011

Adenylate kinase-like activity and phosphotransferase-like activity from $F_1$-ATPase of Escherichia coli was revealed by $^{31}P$ NMR spectroscopy. Incubation of F1-ATPase with ADP in the presence of $Mg^{2+}$ shows the appearance of $^{31}P$ resonances from AMP and Pi, suggesting generation of AMP and ATP by adenylate kinase-like activity and the subsequent hydrolysis to Pi. Incubation of $F_1$-ATPase with ADP in the presence of methanol shows additional peak from methyl phosphate, suggesting phosphotransferase-like activity of $F_1$-ATPase. Both adenylate kinase-like activity and phosphotransferase-like activity has not been reported from $F_1$-ATPase of Escherichia coli. $^{31}P$ NMR could be a valuable tool for the investigation of phosphorous related enzyme.

• 한국미생물·생명공학회지
• /
• 제19권4호
• /
• pp.372-379
• /
• 1991

E.coli ATCC 21990의 aminoglycoside-3'-phosphotransferase(APH(3'))의 신속하고 간편한 정량적 방법을 TLC densitometry를 이용하여 확립하였다. APH(3') 반응생산물인 3' 위치에 인산화된 kanamycin B(3'PKMB)는 silica gel plate에서 cnloroform-methanol-method-ammonia water (3:4:3) 전개용매로 반응물에서 분리되었고, 3'PKMB의 양은 ninhydrin으로 발색 후 densitometry로 측정하였다. APH(3')의 densitometric TLC assay는 좋은 정량적 결과와 재현성을 보였고, 3'-PKMB에 대한 감도는 1.56nmol이었으며 많은 시료의 분석이 한번의 실시로 가능하였다. 이 방법은 aminoglycoside 항생제의 불활화 효소 분석에 응용이 가능하리라 여겨진다.

• Journal of Microbiology and Biotechnology
• /
• 제23권11호
• /
• pp.1529-1535
• /
• 2013

Tuberculosis is a worldwide epidemic disease caused by Mycobacterium tuberculosis, with an estimated one-third of the human population currently affected. Treatment of this disease with aminoglycoside antibiotics has become less effective owing to antibiotic resistance. Recent determination of the crystal structure of the M. tuberculosis Rv3168 protein suggests a structure similar to that of Enterococcus faecalis APH(3')-IIIa, and that this protein may be an aminoglycoside phosphotransferase. To determine whether Rv3168 confers antibiotic resistance against kanamycin, we performed dose-response antibiotic resistance experiments using kanamycin. Expression of the Rv3168 protein in Escherichia coli conferred antibiotic resistance against $100{\mu}M$ kanamycin, a concentration that effected cell growth arrest in the parental E. coli strain and an E. coli strain expressing the $Rv3168^{D249A}$ mutant, in which the catalytic Asp249 residue was mutated to alanine. Furthermore, we detected phosphotransferase activity of Rv3168 against kanamycin as a substrate. Moreover, docking simulation of kanamycin into the Rv3168 structure suggests that kanamycin fits well into the substrate binding pocket of the protein, and that the phosphorylation-hydroxyl-group of kanamycin was located at a position similar to that in E. faecalis APH(3')-IIIa. On the basis of these results, we suggest that the Rv3168 mediates kanamycin resistance in M. tuberculosis, likely through phosphotransferase targeting of kanamycin.

• Journal of mucopolysaccharidosis and rare diseases
• /
• 제2권1호
• /
• pp.13-16
• /
• 2016

Mucolipidosis (ML) II/III are autosomal recessive diseases caused by deficiency of post-translational modification of lysosomal enzymes. The mannose-6-phosphate (M6P) residue in lysosomal enzymes synthesized by N-acetylglucosamine 1-phosphotransferase (GlcNAc-phosphotransferase) serves as recognition marker for trafficking in lysosomes. GlcNAc-phosphotransferase is encoded by GNPTAB and GNPTG. Mutations in GNPTAB cause severe ML II alpha/beta and the attenuated ML III alpha/beta. Whereas mutations in GNPTG cause the ML III gamma, the attenuated type of ML III variant. For the diagnostic approaches, increased urinary oligosaccharides excretion could be a screening test in clinically suspicious patients. To confirm the diagnosis, instead of measuring the activity of GlcNAc phosphotransferase, measuring the enzymatic activities of different lysosomal hydrolases are useful for diagnosis. The activities of several lysosomal hydrolases are decreased in fibroblasts but increased in serum of the patients. In addition, the sequence analysis of causative gene is warranted. Therefore, the confirmatory diagnosis requires a combination of clinical evaluation, biochemical and molecular genetic testing. ML II/III show complex disease manifestations with lysosomal storage as the prime cellular defect that initiates consequential organic dysfunctions. As there are no specific therapy for ML to date, understanding the molecular pathogenesis can contribute to develop new therapeutic approaches ultimately.

• Journal of Applied Biological Chemistry
• /
• 제48권4호
• /
• pp.218-221
• /
• 2005

Nucleotide sequence of Brevibacterium flavum ptsG gene capable of complementing Escherichia coli ZSC113 mutations defective to glucose permease activity of phosphotransferase system was completely determined, and the gene product was compared with other glucose-specific enzyme II ($EII^{Glc}$). A ptsG gene of B. flavum consisted of open reading frame of 2,025 nucleotides putatively encoding polypeptide of 675 amino acid residues and TAA stop codon. Deduced amino acid sequence of B. flavum ($EII^{Glc}$) had high homology with ($EIIs^{Glc}$) of Corynebacterium glutamicum, C. efficiens, and B. lactofermentum. Arrangement of structural domains, IIBCA, of B. flanum ($EII^{Glc}$) protein was identical to that of EIIs belonging to glucose-phosphotransferase system.

• 약학회지
• /
• 제41권4호
• /
• pp.530-532
• /
• 1997

The MICs of various macrolide, lincosamide and streptogramin B antibiotics against highly erythromycin-resistant Escherichia coli 209K strain were evaluated. E. coli 209K showed high MICs against 14-membered macrolides and the relatively weaker resistance to 16-membered macrolides, lincosamides and streptogramin B. The macrolide-phosphotransferase K from E. coli 209K showed greater substrate specificity to the 14-membered macrolide antibiotics than to the 16-membered macrolide antibiotics, lincosamide and streptogramin B. Therefore, it was considered that the high resistance was due to the macrolide-phosphotransferase K.

• 한국미생물·생명공학회지
• /
• 제19권5호
• /
• pp.491-496
• /
• 1991

Aminoglycoside-3'-phosphotransferase(APH(3'))를 생산하는 균주인 E.coli ATCC 21990을 산업적으로 이용하기 위해서 자외선 조사 및 NTG를 처리하고 고농도의 kanamycin B에 내성을 갖는 변이주인 E.coli M1과 M2를 선별하였다. E.coli M1은 단위 균체당 효소 생산성은 높으나 생육속도가 낮아 실용적이질 못했고 주 질소원인 yeast extract를 사용했을때 E.coli M1보다 E.coli M2가 생육속도가 훨씬 빨랐으며 약 2배의 APH(3')을 얻을 수 있었고 산소 가스를 사용하였을 경우는 약 2.5배의 APH(3')을 얻었다.

• 한국생물물리학회:학술대회논문집
• /
• 한국생물물리학회 1998년도 학술발표회
• /
• pp.12-12
• /
• 1998

The interaction between the N-terminal domain of enzyme I (EIN) and the histidine-containing phosphocarrier protein HPr of the Escherichia coli phosphoenolpyruvate：sugar phosphotransferase system has been investigated by Isothermal Titration Calorimetry and heteronuclear magnetic resonance spectroscopy.(omitted)

• Applied Biological Chemistry
• /
• 제36권6호
• /
• pp.557-561
• /
• 1993

Polyethylene glycol(PEG)법 또는 electroporation법으로 제라니움 원형질체에 neomycin phosphotransferase II(nptII) 유전자를 옮기고, 세포내에 도입된 nptII DNA의 존재유무와 발현여부를 조사하였다. Polymerase chain reaction(PCR)을 이용하여 검토한 결과, PEG법을 사용했을 때나 electroporation법을 사용했을 때 모두 세포내에 도입된 nptII DNA가 있음이 확인되었다. 또 이들 세포의 추출물을 전기영동하여 neomycin phosphotransferase 활성을 조사한 결과, 효소활성을 보이는 band가 검출되어 marker gene 으로 도입된 notII 유전자가 세포내에서 발현된다는 것이 확인되었다.

• Journal of mucopolysaccharidosis and rare diseases
• /
• 제2권1호
• /
• pp.1-4
• /
• 2016

Mucolipidosis type II (MLII; MIM#252500) and type III alpha/beta (MLIIIA; MIM#252600) very rare lysosomal storage disease cause by reduced enzyme activity of GlcNAc-1-phosphotransferase. ML II is caused by a total or near total loss of GlcNAc-1-phosphotransferase activity whether enzymatic activity in patient with ML IIIA is reduced. While ML II and ML III share similar clinical features, including skeletal abnormalities, ML II is the more severe in terms of phenotype. ML III is a much milder disorder, being characterized by latter onset of clinical symptoms and slower progressive course. GlcNAc-1-phosphotransferase is encoded by two genes, GNPTAB and GNPTG, mutations in GNPTAB give rise to ML II or ML IIIA. To date, more than 100 different GNPTAB mutations have been reported, causing either ML II or ML IIIA. Despite development of new diagnostic approach and understanding of disease mechanism, there is no specific treatment available for patients with ML II and ML IIIA yet, only supportive and symptomatic treatment is indicated.